Home THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY

DISEASES FOR EXCLUSION

Table 3: Diseases that must be excluded for an iMCD diagnosis1

AUTOIMMUNE
DISEASE 		MALIGNANT/
LYMPHO-PROLIFERATIVE
DISORDERS 		INFECTION-RELATED
DISORDERS
Rheumatoid arthritis Lymphoma (Hodgkin and non-Hodgkin) HHV-8 infection
Systemic lupus erythematosus Multiple myeloma Clinical EBV-lymphoproliferative disorders e.g. infectious mononucleosis or chronic active EBV
Adult-onset Still disease Primary lymph node plasmacytoma Inflammation and adenopathy caused by other uncontrolled infections e.g. toxoplasmosis, HIV, active TB
Autoimmune lymphoproliferative syndrome FDC sarcoma -
Juvenile idiopathic arthritis POEMS syndrome* -

BACK

 

*  MCD patients with POEMS are distinguished from iMCD because POEMS has a different natural history and therapeutic approach to iMCD.

References

  1. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-57.
  2. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163-75.
  3. Sitenga J, Aird G, Ahmed A, Silberstein PT. Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease. Patient Relat Outcome Meas. 2018;9:35-41.
  4. Srkalovic G, Marijanovic, I., Srkalovic, M.B., Fjagenbaum, D.C.,. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease. Bosn J Basic Med Sci 2017 [Available from: http://www.bjbms.org/ojs/index.php/bjbms/article/view/1930].
  5. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59 Suppl 1:i21-7.

EUSA Sylvant © 2021 EUSA Pharma      Date of prep: November 2021    GL-SIL-2100101

This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.

© 2021 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ